Lung Cancer Diagnostic Test Market, by Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others), By Cancer Type (Non-small cell lung cancer and Small Cell Lung Cancer), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2029

Lung Cancer Diagnostic Test Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 4.07 billion by 2030 and is anticipated to register a CAGR of 7.50%.

Lung cancer is a cancer that develops in the lungs. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLLC) are the two main forms of lung cancer, and they are treated differently (SCLC). According to the American Cancer Society, non-small cell lung cancer accounts for 80 percent to 85 percent of lung cancer cases, while small cell lung cancer accounts for 10% to 15% of cases. Oat cell lung cancer is another name for small cell lung cancer. Biomarkers, imaging tests, and biopsy are some of the most essential lung cancer screening techniques. Lung cancer starts in the lungs and can spread to the lymph nodes or other body organs, including the brain. Cancer that has progressed to other organs can potentially spread to the lungs. Metastases are the spread of cancer cells from one organ to another. Small cell and non-small cell lung tumours are the two most common kinds of lung cancer. These kinds of lung cancer grow and respond to treatment in different ways. Non-small cell lung cancer is more prevalent than small cell lung cancer, according to the American Cancer Society. Lung cancer symptoms range from person to person. Symptoms of the lungs affect some persons.

Impact of Covid-19 pandemic on market

Lung cancer screening programs had been largely suspended during the outbreak. The demand for cancer screening tests increased as a result of the shutdown. Prior to the pandemic, lung cancer diagnosis was the top cause of cancer diagnosis and mortality worldwide, accounting for 11.6 percent of new cases and 18.4 percent of deaths, according to an article published in the Official Journal of the Asia Pacific Society of Respirology in 2019. The majority of lung cancer patients are discovered at an advanced stage, which accounts for the poor prediction of symptoms. Referrals to lung cancer services dropped sharply during the pandemic, owing to fears of an increase in late-stage presentations and higher fatality rates.

Increasing R&D activities and product approvals

The increased focus on lung cancer diagnosis and screening test research and development is one of the major reasons driving market expansion. For example, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based technique in April 2020 that enables for the early detection of lung cancer via a simple urine test. The method detects biomarker produced by peptide-coated nanoparticles interacting with disease-associated proteases in the tumour microenvironment. The urine test was shown to detect tumours as tiny as 2.8 mm in two separate animal models of lung cancer. The researchers anticipate that this type of noninvasive diagnosis will reduce the number of false positives associated with current test methods and aid in the early detection of more malignancies.

When there are no symptoms of lung cancer, a lung cancer screening is performed. People are less aware of the importance of screening due to which it can hamper market expansion. False positive reports are also predicted to hinder market expansion. For instance, researchers from the University of Pittsburgh and the UPMC Hillman Cancer Center discovered in March 2019 that 96 percent of persons who test positive for lung cancer do not have a malignant tumour.

Lung Cancer Diagnostic Test Market is segmented by Test Type, Cancer Type, End-User and Region.

On the basis of Test Type, the Lung Cancer Diagnostic Test Market is segmented into Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others. On the basis of Cancer Type, the target market is segmented into Non-small cell lung cancer and Small Cell Lung Cancer. Based on End User the market is segmented into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others.

Regional Insights:

On region the Lung Cancer Diagnostic Test Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. During the projected period, North America is expected to be the most dominating region in the lung cancer diagnostic and screening market. The rising number of inorganic development tactics used by North American leading competitors, such as acquisitions and mergers, are prominent factors driving the lung cancer diagnostic and screening market in North America. For example, in April 2016, AbbVie, a major biopharmaceutical company, announced the purchase of Stemcentrx and its key late-stage product, rovalpituzumab tesirine (Rova-T), which is now being studied in small cell lung cancer registrational trials (SCLC). Rova-T is a new biomarker-specific therapy produced from cancer stem cells that targets the delta-like protein 3 (DLL3), which is found in over 80% of SCLC patient tumours but not in healthy tissue.

Lung Cancer Diagnostic Test Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Lung Cancer Diagnostic Test Market report based on Product Type, Application, End User and Region.

Lung Cancer Diagnostic Test Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the Lung Cancer Diagnostic Test Market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.

• In January 2021, Roche introduced their Cobas Pulse System in select countries that receive the CE Mark. Roche Diagnostic’s newest generation of connected point-of-care solutions is the product. Professional blood glucose management is available with the new launch.

• Abbott
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Illumina Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Thermo Fischer Scientific
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• QIAGEN
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Quest Diagnostics Incorporated
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• NeoGenomics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• NanoString
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Myriad Genetics Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Danaher
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Agilent Technologies, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies